In this article, we will take a look at the 12 stocks that will double in 2025.
The Fed’s Probable Path and its Impact on Earnings
A lot is happening in the market, especially within the growth sectors. The launch of DeepSeek has caused significant uproar across the tech market in the United States, and with key names reporting earnings this week, investors are uncertain about how the market is going to play out in 2025. On top of that, the question mark on the Fed’s future actions poses yet another blow to investor sentiment. On January 30, Jim Bullard, former St. Louis Fed president, joined Market Domination on Yahoo Finance to discuss his market thesis amid the Fed’s decisions to keep rates steady.
Bullard suggested that the Fed has been signaling a slowdown in the easing cycle for the past 90 days and that the current situation is not unexpected. Speaking of voting changes, Bullard stated that this decision was more like an open-shut case meaning that any voting changes would have made no difference in the decision to keep rates steady. While some regard the Fed’s decision of a 100 basis point cut as hasty and “too much”, Bullard remains persistent that it was the “right call” and a step in the right direction.
As for the current policy rate, Bullard emphasized that the Fed is in great shape to keep rates steady and must wait for inflation data before any decisions have been made. He added that if inflation is sticky at where “it is right now” then a rate cut in 2025 is highly unlikely. On the flipside, he suggested that if inflation begins to rise again, the Fed may raise rates again.
Similarly, on January 29, Stuart Kaiser, head of US equity trading strategy at Citi, appeared in an interview on Yahoo Finance to shed light on the tech landscape and how the earnings may be impacted due to the Fed’s decision. Kaiser emphasized that the earnings season is very important, but the commentary of CEOs is more crucial at this point. He suggested, that CEOs will have to explain their capital expenditures and the value they expect to derive from these hefty expenses to garner positive investor sentiment.
While Kaiser is still positive about the sector, he stated that he is not an aggressive buyer and will likely remain cautious. He added that to circle back to buying into the sector, the need for market clarity is more crucial than ever, reiterating that commentary from CEOs is necessary. He also suggested that the DeepSeek development is huge for the AI market and puts pressure on only a handful of companies in the sector. While he remained cautiously bullish on the tech sector, he shared concern over utilities not being able to recover as much with a lack of incremental buying, despite having significant energy demand from AI use-cases.
Speaking of the Fed’s meeting, Kaiser suggested that the updated economic data has been in line with their forecasts, and while the decision matters, from a data perspective there is not much to say. Despite market volatility, some stocks are expected to perform exceptionally well in 2025 due to their exemplary positions in their respective industries. That said, let’s take a look at the 12 stocks that will double in 2025.
A financial analyst looking at a monitor displaying the stocks of the public company.
Our Methodology
We used similar rankings on the internet to come up with a list of names expected to double in 2025. We only focused on companies with a market cap of at least $2 billion. We then examined the analyst upside surrounding 25 stocks and picked the 12 stocks with an upside of at least 100%, as of January 29, 2025. We have also included the hedge fund sentiment around each stock, as of Q3 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
12 Stocks That Will Double in 2025
12. ImmunityBio, Inc. (NASDAQ:IBRX)
Analyst Upside as of January 29, 2025: 122%
Number of Hedge Fund Holders: 8
ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company working to develop therapies that enhance the immune system of patients, instead of weakening it. Since its inception in 2014, the company has become a clinical-stage biotechnology company with 27 clinical trials in process. Of these, 18 are in phase 2 and phase 3 trials. The company’s expansion strategy is exemplary. On January 29, ImmunityBio, Inc. (NASDAQ:IBRX) announced a collaboration with BeiGene on confirmatory phase 3 trials of Anktiva in non-small cell lung cancer. Similarly, on January 27, in an impressive feat, the company announced that the European Medicines Agency (EMA) had begun assessing the marketing authorization for IBRX’s start drug, Anktiva.
IBRX’s accelerating position in the biotechnology industry is prominent and is deriving the right attention from analysts and investors. On January 10, Justin Zelin, an analyst at BTIG, initiated the stock with a buy rating and a price target of $6. The company’s lead product Anktiva received approval following compelling response rates and durability results, explaining the thesis behind the rating. The analyst also believes that ImmunityBio’s (NASDAQ:IBRX) partnership with the Serum Institute of India for the development of recombinant BCG is an impressive approach to its long-term supply chain management.
Overall, IBRX boasts a solid growth opportunity evident from its product approvals and key strategic partnerships. This explains why analysts are bullish on the stock and their median price target of $8 points to an upside of 122%
11. Apogee Therapeutics, Inc. (NASDAQ:APGE)
Analyst Upside as of January 28, 2025: 123%
Number of Hedge Fund Holders: 21
Apogee Therapeutics, Inc. (NASDAQ:APGE) is a clinical-stage biotechnology company focused on treating immunological and inflammatory diseases. The company’s pipeline is vast, and it has the potential to treat various dermatological, respiratory, and gastroenterological conditions. Over the past few months, the company has accelerated trials for key drugs, participated in crucial conferences, and revealed important updates from trials.
For example, in its Q3 2024 earnings release, Apogee Therapeutics, Inc. (NASDAQ:APGE) announced positive results for the APG777 Phase 1 trial and revealed that the company was on track to release Phase 2 Part A data for APG777 in the second half of 2025. The company also announced that APG333 has the potential to offer top-notch efficacy across several respiratory conditions, marking a solid feat for the company’s growth potential. Similarly, APGE also advanced plans for combination studies, starting with the first clinical trial of the APG777 and APG990 combination in 2025.
By the end of the third quarter of 2024, Apogee Therapeutics, Inc. (NASDAQ:APGE) had $754 million in cash and cash equivalents, promising smooth operations into 2028. The company plans to continue building its portfolio with transformative therapies and with a supportive cash position, APGE indeed serves as an emerging leader in the biotech industry.
